Correction to: Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes (Medical Oncology, (2015), 32, 3, (43), 10.1007/s12032-015-0487-0);Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes

Medical Oncology

Volumn 32, Issue 3, 2015, Pages

  Chen, Weiliang ^a   Wang, Donghai ^a   Du, Xinwen ^b   He, Ying ^a   Chen, Songyu ^a   Shao, Qianqian ^a   Ma, Chao ^a   Huang, Bin ^a   Chen, Anjing ^a   Zhao, Peng ^a   Qu, Xun ^a   Li, Xingang ^a  

^a SHANDONG UNIVERSITY   (China)

^b Laizhou People's Hospital   (China)

Author keywords

Astrocyte; Chemoresistance; Glioma; Temozolomide; Vincristine

Indexed keywords

CONNEXIN 43; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; CALCIUM; DACARBAZINE;

APOPTOSIS; ARTICLE; ASTROCYTE; CELL COMMUNICATION; CELL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; GAP JUNCTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; COCULTURE; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTROCYTES; BRAIN NEOPLASMS; CALCIUM; CELL COMMUNICATION; COCULTURE TECHNIQUES; CONNEXIN 43; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GAP JUNCTIONS; GENE KNOCKDOWN TECHNIQUES; GLIOMA; HUMANS; TUMOR MICROENVIRONMENT; VINCRISTINE;

EID: 84961290723     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-021-01564-0     Document Type: Erratum

References (44)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.1056/NEJMoa043330.
2. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14(10):2900–8. doi:10.1158/1078-0432.CCR-07-1719.
3. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem. 2008;312(1–2):71–80. doi:10.1007/s11010-008-9722-8.
4. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6(7):2585–97.
5. Stanton RA, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011;31(3):443–81. doi:10.1002/med.20242.
6. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012;21(4):488–503. doi:10.1016/j.ccr.2012.02.017.
7. Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 2012;15(1–2):39–49. doi:10.1016/j.drup.2012.01.006.
8. Zhang W, Huang P. Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Cancer Biol Ther. 2011;11(2):150–6.
9. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–4. doi:10.1038/nature11183.
10. Muerkoster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res. 2004;64(4):1331–7.
11. Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol. 2007;170(5):1546–60. doi:10.2353/ajpath.2007.061004.
12. Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007;28(3):138–45. doi:10.1016/j.it.2007.01.005.
13. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2012;60(3):502–14.
14. Nagano N, Sasaki H, Aoyagi M, Hirakawa K. Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells. Acta Neuropathol. 1993;86(2):117–25.
15. Lal PG, Ghirnikar RS, Eng LF. Astrocyte-astrocytoma cell line interactions in culture. J Neurosci Res. 1996;44(3):216–22. doi:10.1002/(SICI)1097-4547(19960501)44:3<216:AID-JNR2>3.0.CO;2-J.
16. Iadecola C, Nedergaard M. Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007;10(11):1369–76. doi:10.1038/nn2003.
17. Trendelenburg G, Dirnagl U. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia. 2005;50(4):307–20. doi:10.1002/glia.20204.
18. Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci. 2004;24(9):2143–55. doi:10.1523/JNEUROSCI.3547-03.2004.
19. Yang C, Rahimpour S, Yu AC, Lonser RR, Zhuang Z. Regulation and dysregulation of astrocyte activation and implications in tumor formation. Cell Mol Life Sci. 2013;. doi:10.1007/s00018-013-1274-8.
20. Sofroniew MV. Reactive astrocytes in neural repair and protection. Neurosci. 2005;11(5):400–7. doi:10.1177/1073858405278321.
21. Mahesh VB, Dhandapani KM, Brann DW. Role of astrocytes in reproduction and neuroprotection. Mol Cell Endocrinol. 2006;246(1–2):1–9. doi:10.1016/j.mce.2005.11.017.
22. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610–22. doi:10.1038/nrn2175.
23. Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia. 2011;13(3):286–98.
24. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia. 2010;12(9):748–54.
25. Krysko DV, Leybaert L, Vandenabeele P, D’Herde K. Gap junctions and the propagation of cell survival and cell death signals. Apoptosis Int J Progr Cell Death. 2005;10(3):459–69. doi:10.1007/s10495-005-1875-2.
26. Charles AC, Naus CC, Zhu D, Kidder GM, Dirksen ER, Sanderson MJ. Intercellular calcium signaling via gap junctions in glioma cells. J Cell Biol. 1992;118(1):195–201.
27. Zhang W, Couldwell WT, Simard MF, Song H, Lin JH, Nedergaard M. Direct gap junction communication between malignant glioma cells and astrocytes. Cancer Res. 1999;59(8):1994–2003.
28. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4(7):552–65. doi:10.1038/nrm1150.
29. 2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008;8(5):361–75. doi:10.1038/nrc2374.
30. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7–35. doi:10.1007/s00401-009-0619-8.
31. Clavreul A, Etcheverry A, Chassevent A, Quillien V, Avril T, Jourdan ML, et al. Isolation of a new cell population in the glioblastoma microenvironment. J Neurooncol. 2012;106(3):493–504. doi:10.1007/s11060-011-0701-7.
32. Oliveira R, Christov C, Guillamo JS, de Bouard S, Palfi S, Venance L, et al. Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas. BMC Cell Biol. 2005;6(1):7. doi:10.1186/1471-2121-6-7.
33. Sun P, Liu Y, Ying H, Li S. Action of db-cAMP on the bystander effect and chemosensitivity through connexin 43 and Bcl-2-mediated pathways in medulloblastoma cells. Oncol Rep. 2012;28(3):969–76. doi:10.3892/or.2012.1900.
34. Carystinos GD, Alaoui-Jamali MA, Phipps J, Yen L, Batist G. Upregulation of gap junctional intercellular communication and connexin 43 expression by cyclic-AMP and all-trans-retinoic acid is associated with glutathione depletion and chemosensitivity in neuroblastoma cells. Cancer Chemother Pharmacol. 2001;47(2):126–32.
35. Robe PA, Nguyen-Khac M, Jolois O, Rogister B, Merville MP, Bours V. Dexamethasone inhibits the HSV-tk/ganciclovir bystander effect in malignant glioma cells. BMC Cancer. 2005;5:32. doi:10.1186/1471-2407-5-32.
36. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006;12(15):4738–46. doi:10.1158/1078-0432.CCR-06-0596.
37. Rouach N, Avignone E, Meme W, Koulakoff A, Venance L, Blomstrand F, et al. Gap junctions and connexin expression in the normal and pathological central nervous system. Biol Cell. 2002;94(7–8):457–75.
38. Warn-Cramer BJ, Lau AF. Regulation of gap junctions by tyrosine protein kinases. Biochim Biophys Acta. 2004;1662(1–2):81–95. doi:10.1016/j.bbamem.2003.10.018.
39. Soroceanu L, Manning TJ Jr, Sontheimer H. Reduced expression of connexin-43 and functional gap junction coupling in human gliomas. Glia. 2001;33(2):107–17.
40. Huang RP, Hossain MZ, Huang R, Gano J, Fan Y, Boynton AL. Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer. 2001;92(1):130–8.
41. Gielen PR, Aftab Q, Ma N, Chen VC, Hong X, Lozinsky S, et al. Connexin43 confers temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology. 2013;75:539–48. doi:10.1016/j.neuropharm.2013.05.002.
42. Munoz JL, Rodriguez-Cruz V, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis. 2014;5:e1145. doi:10.1038/cddis.2014.111.
43. Decrock E, Krysko DV, Vinken M, Kaczmarek A, Crispino G, Bol M, et al. Transfer of IP(3) through gap junctions is critical, but not sufficient, for the spread of apoptosis. Cell Death Differ. 2012;19(6):947–57. doi:10.1038/cdd.2011.176.
44. Gagliano N, Costa F, Cossetti C, Pettinari L, Bassi R, Chiriva-Internati M, et al. Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. Oncol Rep. 2009;22(6):1349–56.